Certain Class B Ordinary Shares of Ibere Pharmaceuticals are subject to a Lock-Up Agreement Ending on 24-AUG-2021. These Class B Ordinary Shares will be under lockup for 180 days starting from 25-FEB-2021 to 24-AUG-2021.

Details:
The sponsor and officers and directors have agreed that, for a period of 180 days from the date of this prospectus, they will not, without the prior written consent of Raymond James & Associates, Inc. offer, sell, contract to sell, grant any option to sell (including any short sale), pledge, transfer or otherwise dispose of, directly or indirectly, any units, warrants, ordinary shares or any other securities convertible into, or exercisable, or exchangeable for, ordinary shares currently or hereafter owned either of record or beneficially, or publicly announce an intention to do any of the foregoing; provided, however, that issuer may (1) issue and sell the private placement warrants, (2) issue and sell the additional units to cover our underwriters' overallotment option (if any), (3) register with the SEC pursuant to an agreement to be entered into concurrently with the issuance and sale of the securities in this offering, the resale of the private placement warrants and Class A ordinary shares issuable upon exercise of the warrants and conversion of the founder shares and (4) issue securities in connection with an initial business combination. Raymond James & Associates, Inc., in its sole discretion may release any of the securities subject to these lock-up agreements at any time without notice.